Skip to main content

Table 1 Patient characteristics and median survival from the time of treatment initiation, mRCC patients, Estonia 2004–2012

From: Changes in therapy and survival of metastatic renal cell carcinoma in Estonia

 

Total

Treatment group 1a

Treatment group 2b

N

%

N

%

N

%

p-value

Total

380

100

125

100

255

100

 

Age group

 15–59

120

32

42

34

78

31

p = 0.706

 60–69

134

35

45

36

89

35

 

 70+

126

33

38

30

88

35

 

Sex

 Male

252

66

83

66

169

66

p = 0.981

 Female

128

34

42

34

86

34

 

Histology

 Clear Cell

313

82

82

66

231

91

p < 0.001

 Non-Clear cell

61

16

39

31

22

9

 

 Unknown

6

2

4

3

2

1

 

Nephrectomy

 Done

314

83

102

81

212

83

p = 0.712

 Not done

61

16

22

18

39

15

 

 Other

5

1

1

1

4

2

 

Treatment started

 2004–2007

137

36

107

86

30

12

p < 0.001

 2008–2012

243

64

18

14

225

88

 

Prognostic group (only 2008–2012)

 Favorable

50

21

1

6

49

22

p = 0.03

 Intermediate

153

63

10

55

143

64

 

 Poor

9

4

1

6

8

4

 

 Unknown

31

13

6

33

25

11

 

 Median survival in months (95% CI)

13.7 (11.3–16.2)

 

7.6 (6.4–8.6)

 

19.8 (15.6–22.9)

 

p < 0.001

Survival#

 12-month

53% (48–58)

 

30% (22–38)

 

65% (59–71)

  

 24-month

34% (29–38)

 

14% (9–21)

 

43% (37–49)

  

 36-month

24% (20–28)

 

9% (5–15)

 

31% (25–37)

  
  1. a INFa only
  2. b INFa followed by targeted agents or targeted agents only
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us